| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S002800050071 |
| P8608 | Fatcat ID | release_vagzksccnvdzdimosxpj2akigi |
| P698 | PubMed publication ID | 8306413 |
| P50 | author | Franco Muggia | Q30512486 |
| P2093 | author name string | K K Chan | |
| J J Zheng | |||
| P2860 | cites work | Cyclophosphamide cystitis. Studies aimed at its minimization | Q28323044 |
| Cyclophosphamide cystitis—Identification of acrolein as the causative agent | Q28327805 | ||
| Cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds | Q28337756 | ||
| Alkylating properties of phosphoramide mustard | Q28341980 | ||
| Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective | Q34200741 | ||
| Pharmacokinetics of cyclophosphamide in Kenyan Africans | Q34512908 | ||
| The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy | Q34519153 | ||
| Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide | Q36047370 | ||
| Ifosfamide--pharmacologic overview. | Q38616118 | ||
| Pharmacokinetics of cyclophosphamide in man | Q39986730 | ||
| Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration | Q41429850 | ||
| Kinetics of phosphoramide mustard hydrolysis in aqueous solution | Q42230124 | ||
| Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide | Q43410903 | ||
| Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite | Q44749559 | ||
| Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat | Q46000136 | ||
| Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide. | Q53578028 | ||
| Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin. | Q54137859 | ||
| Isolation and mass spectral identification of blood metabolities of cyclophosphamide: Evidence for phosphoramide mustard as the biologically active metabolite | Q66931110 | ||
| Identification of phosphorodiamidic acid mustard as a human metabolite of cyclop hosphamide | Q66931794 | ||
| Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy | Q67249744 | ||
| Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans | Q67585033 | ||
| The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity | Q67796451 | ||
| Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites | Q67796476 | ||
| Ifosfamide pharmacokinetics and neurotoxicity | Q68082516 | ||
| Combined thin-layer chromatography—photography—densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites | Q68488517 | ||
| In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes | Q68772427 | ||
| [Studies on the spontaneous decomposition of 4-hydroxyphosphamide and 4-hydroperoxyphosphamide by means of thin-layer chromatography] | Q68941328 | ||
| Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial | Q68949308 | ||
| Analysis of phosphoramide mustard by reversed-phase ion pair high pressure liquid chromatography | Q69175397 | ||
| A biologically active metabolite of cyclophosphamide | Q69500918 | ||
| Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite | Q69516308 | ||
| Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo | Q69551574 | ||
| Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide | Q69733875 | ||
| Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation | Q70412322 | ||
| Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide) | Q70589430 | ||
| Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia | Q70589434 | ||
| Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites | Q70657594 | ||
| Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test | Q70797964 | ||
| Simple reliable method for chronic cannulation of the jugular vein for pharmacokinetic studies in rats | Q71074108 | ||
| Comparison of cytotoxic action of iphosphamide and cyclophosphamide | Q71110478 | ||
| Kinetics of cyclophosphamide biotransformation in vivo | Q71127536 | ||
| [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)] | Q71143704 | ||
| Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide | Q71393836 | ||
| Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats | Q71661503 | ||
| Clinical toxicologic study of cyclohexylamine salt of N,N-bis(2-chlorethyl)phosphorodiamidic acid (NSC-69945; OMF-59) | Q72255780 | ||
| Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes | Q72581661 | ||
| Half-life of oxazaphosphorines in biological fluids | Q72592442 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 391-398 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Preclinical pharmacokinetics and stability of isophosphoramide mustard | |
| P478 | volume | 33 |
| Q60924205 | An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect |
| Q27000814 | Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy |
| Q37361514 | Stereoselective pharmacokinetics of ifosfamide in male and female rats |
Search more.